NCT03544736

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC-study) - a Phase I/II Trial

Extracted Fields (from Registry)
Protocol IDNCT03544736
Registration Date2018-06-04
Statusactive, not recruiting
SponsorOslo University Hospital
CountryNorway
Industrynot industry
Blindingunblinded
Center Typesingel-center RCT
Scopenational RCT
First Patient In2018-04-26
Last Patient Out2040-12-31
Publicationn
Gender %ALL
Mean Age18 Years -
LLM Classifications (Side-by-Side)
Field GLM
glm-5.1
9020ms / 10204 tok
CLAUDE
claude-sonnet-4-20250514
7384ms / 11739 tok
OPENAI
gpt-4o
3100ms / 10013 tok
Review
rct_type N/A N/A N/A OK
cancer_status Cancer Cancer Cancer OK
non_cancer_spec N/A N/A N/A OK
setting_patient outpatient outpatient outpatient OK
setting_place hospital hospital hospital OK
feasibility feasibility RCT feasibility RCT feasibility RCT OK
intervention_pharmacologic yes yes yes OK
intervention_chemo_immuno_radio yes yes yes OK
intervention_complementary no no no OK
intervention_device no no no OK
intervention_psychological no no no OK
intervention_complex yes no
shaky reasoning
✓ Unanimous Initial: no
yes yes → yes
shaky reasoning
✓ Unanimous Initial: yes Requery: yes — The intervention combines multiple distinct treatment modalities (immunotherapy with nivolumab, radiotherapy, chemotherapy, and surgery) that interact together as an integrated multicomponent treatment approach for esophageal cancer.
yes yes → yes
shaky reasoning
✓ Unanimous Initial: yes Requery: yes — The intervention combines different types, specifically pharmacological (Nivolumab) with radiotherapy and chemotherapy, integrating these distinct components across multiple cohorts.
OK
intervention_acp no no no OK
intervention_music no no no OK
intervention_screening no no no OK
intervention_palliative no no no OK
intervention_education no no no OK
intervention_digital no no no OK
intervention_other no no no OK
outcome_symptom no no no OK
outcome_qol yes yes yes OK
outcome_dignity no no no OK
outcome_cost no no no OK
outcome_other yes yes yes OK
pharmacologic_sub immunotherapy immunotherapy immunotherapy OK
Back to Studies